F M Investments LLC Acquires 1,611 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

F M Investments LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,426 shares of the medical equipment provider’s stock after purchasing an additional 1,611 shares during the period. F M Investments LLC’s holdings in Intuitive Surgical were worth $10,662,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Atala Financial Inc bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at $25,000. Berbice Capital Management LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter valued at $26,000. BankPlus Trust Department bought a new position in shares of Intuitive Surgical during the 4th quarter valued at approximately $28,000. Hurley Capital LLC purchased a new stake in Intuitive Surgical in the 4th quarter worth about $28,000. Finally, Summit Securities Group LLC bought a new position in Intuitive Surgical in the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other news, EVP Brian Edward Miller sold 8,900 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the transaction, the executive vice president now directly owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock valued at $17,691,621 in the last three months. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Up 14.3 %

NASDAQ:ISRG opened at $522.95 on Thursday. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The firm has a market capitalization of $186.26 billion, a PE ratio of 81.58, a PEG ratio of 5.85 and a beta of 1.55. The firm’s fifty day simple moving average is $536.22 and its 200 day simple moving average is $532.26.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Citigroup boosted their target price on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. Barclays increased their target price on Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Leerink Partners lifted their price target on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Erste Group Bank downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 17th. Finally, Bernstein Bank upped their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $611.86.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.